CD274 and non-small cell lung carcinoma: Among patients initiating a first-line PD-(L)1 inhibitor monotherapy in the overall population with ECOG PS0-2, the median OS was 15.2 and 12.9 months for patients with NSQ and SQ advanced NSCLC, respectively (Figure 1; Table 3).